RT Journal Article
SR Electronic
T1 Assessing the contribution of gut-to-lung translocation to bacterial colonization and antibiotic resistance in an ICU patient
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.17.22269403
DO 10.1101/2022.01.17.22269403
A1 Wheatley, Rachel M
A1 Caballero, Julio Diaz
A1 van der Schalk, Thomas E.
A1 De Winter, Fien HR
A1 Kapel, Natalia
A1 Recanatini, Claudia
A1 Timbermont, Leen
A1 Kluytmans, Jan
A1 Esser, Mark
A1 Lacoma, Alicia
A1 Prat-Aymerich, Cristina
A1 Oliver, Antonio
A1 Kumar-Singh, Samir
A1 Malhotra-Kumar, Surbhi
A1 MacLean, R. Craig
A1 WP3A working group
YR 2022
UL http://medrxiv.org/content/early/2022/01/18/2022.01.17.22269403.abstract
AB Bacteria have the potential to migrate between sites in the human body, but the dynamics and consequences of within-host translocation remain poorly understood. Here we investigate the link between gut and lung Pseudomonas aeruginosa populations in an intensively sampled ICU patient using a combination of genomics, isolate phenotyping, host immunity profiling, and clinical data. Crucially, we show that lung colonization was driven by the repeated translocation of bacterial clones from the gut. Meropenem treatment for a suspected urinary tract infection selected for elevated resistance in both the gut and lung. However, resistance was driven by parallel evolution and organ-specific selective pressures, and within-host transmission had only a minor impact on AMR. These findings suggest that reducing intestinal colonization of Pseudomonas may be an effective way to prevent lung infections in critically ill patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Wellcome Trust Grant (106918/Z/15/Z) and the Innovative Medicines Initiative Joint Undertaking under COMBACTE-MAGNET (Combatting Bacterial Resistance in Europe-Molecules against Gram-negative Infections, grant agreement no. 115737) and COMBACTE-NET (Combatting Bacterial Resistance in Europe-Networks, grant agreement no. 115523), resources of which are composed of financial contribution from the European Union's Seventh Framework Program (FP7/2007-2013) and EFPIA companies' in kind contribution.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Research Ethics Committee of the Germans Trias i Pujol University Hospital. This study was conducted according to the principles of the Declaration of Helsinki, in accordance with the Medical Research Involving Human Subjects Act and local guidelines in the participating countries.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.